Novel radiopeptide shows high efficacy without high toxicity
Added: Tuesday 2 August 2011
A new radiopeptide called 213Bi-DOTATOC appears to show high efficacy in treating neuroendocrine tumours without high toxicity. Appropriate dosing is a key focus of research into alpha therapy, because of its high cytotoxicity; the new radiopeptide offers hope that more powerful, effective doses can be used.
In order to be able to see the content from the www.medscape.com pages, please create first a free account at following link: